FCCC LOGO Faculty Publications
Kim B , Wang S , Lee JM , Jeong Y , Ahn T , Son DS , Park HW , Yoo HS , Song YJ , Lee E , Oh YM , Lee SB , Choi J , Murray JC , Zhou Y , Song PH , Kim KA , Weiner LM
Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy
Oncogene. 2015 Feb 26;34(9) :1083-93
PMID: 24662823   
Back to previous list
Met is a receptor tyrosine kinase that promotes cancer progression. In addition, Met has been implicated in resistance of tumors to various targeted therapies such as epidermal growth factor receptor inhibitors in lung cancers, and has been prioritized as a key molecular target for cancer therapy. However, the underlying mechanism of resistance to Met-targeting drugs is poorly understood. Here, we describe screening of 1310 genes to search for key regulators related to drug resistance to an anti-Met therapeutic antibody (SAIT301) by using a small interfering RNA-based synthetic lethal screening method. We found that knockdown of 69 genes in Met-amplified MKN45 cells sensitized the antitumor activity of SAIT301. Pathway analysis of these 69 genes implicated fibroblast growth factor receptor (FGFR) as a key regulator for antiproliferative effects of Met-targeting drugs. Inhibition of FGFR3 increased target cell apoptosis through the suppression of Bcl-xL expression, followed by reduced cancer cell growth in the presence of Met-targeting drugs. Treatment of cells with the FGFR inhibitors substantially restored the efficacy of SAIT301 in SAIT301-resistant cells and enhanced the efficacy in SAIT301-sensitive cells. In addition to FGFR3, integrin beta3 is another potential target for combination treatment with SAIT301. Suppression of integrin beta3 decreased AKT phosphorylation in SAIT301-resistant cells and restored SAIT301 responsiveness in HCC1954 cells, which are resistant to SAIT301. Gene expression analysis using CCLE database shows that cancer cells with high levels of FGFR and integrin beta3 are resistant to crizotinib treatment, suggesting that FGFR and integrin beta3 could be used as predictive markers for Met-targeted therapy and provide a potential therapeutic option to overcome acquired and innate resistance for the Met-targeting drugs.
1476-5594 Kim, B Wang, S Lee, J M Jeong, Y Ahn, T Son, D-S Park, H W Yoo, H-S Song, Y-J Lee, E Oh, Y M Lee, S B Choi, J Murray, J C Zhou, Y Song, P H Kim, K-A Weiner, L M P30 CA051008/CA/NCI NIH HHS/United States R01 CA050633/CA/NCI NIH HHS/United States Journal Article England Oncogene. 2015 Feb 26;34(9):1083-93. doi: 10.1038/onc.2014.51. Epub 2014 Mar 24.